Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2025 | Evaluating the current treatment landscape of urothelial carcinoma

Rohit Jain • 14 Feb 2025
GU Cancers 2025
Bladder Cancer Genitourinary Cancer Urothelial Carcinoma Antibodies Checkpoint Inhibitors Enfortumab vedotin Erdafitinib Sacituzumab govitecan

Rohit Jain, MD, MPH, Weill Cornell Medicine, New York, NY, comments on the evolving landscape of treatments for metastatic urothelial carcinoma. Enfortumab vedotin (EV) with pembrolizumab has become a first-line treatment, and erdafitinib is currently used as a second-line treatment, but potential future combinations, such as EV with pembrolizumab and erdafitinib, or EV with pembrolizumab and sacituzumab govitecan, could be novel additions to the treatment armamentarium. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Rohit Jain

Treating enfortumab vedotin related AEs in urothelial carcinoma
0:59
Treating enfortumab vedotin related AEs in urothelial carcinoma
Rohit Jain • 14 Feb 2025
ETCTN 10483: erdafitinib and EV in FGFR3/2-altered urothelial cancer
2:49
ETCTN 10483: erdafitinib and EV in FGFR3/2-altered urothelial cancer
Rohit Jain • 14 Feb 2025
Sequencing ADCs and finding novel biomarkers for urothelial carcinoma
0:46
Sequencing ADCs and finding novel biomarkers for urothelial carcinoma
Rohit Jain • 26 Jan 2024
Ipilimumab plus nivolumab with sacituzumab govitecan in mUC
0:57
Ipilimumab plus nivolumab with sacituzumab govitecan in mUC
Rohit Jain • 26 Jan 2024

Related Videos

Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Which patients with kidney cancer may benefit from SABR treatment?
1:58
Which patients with kidney cancer may benefit from SABR treatment?
Shankar Siva • 16 May 2026
Management of brain metastasis in patients with poor-risk testicular cancer
1:03
Management of brain metastasis in patients with poor-risk testicular cancer
Darren Feldman • 30 May 2026
The content of VJOncology is intended for healthcare professionals